Hearing loss · children with cancer treated with platinum‐based therapy
Continuous platinum infusion showed no clear difference in hearing loss (asymptomatic and symptomatic disease according to… compared with bolus platinum infusion (low certainty).
1 finding from 1 review
Tinnitus ‐ not reported · children with cancer treated with platinum‐based therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival ‐ not reported · children with cancer treated with platinum‐based therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Event‐free survival · children with cancer treated with platinum‐based therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Tumour response · children with cancer treated with platinum‐based therapy
1 finding from 1 review
no estimate extracted
1 study · 1 participants
Low
Adverse effects: toxic death (no definition provided) · children with cancer treated with platinum‐based therapy
Continuous platinum infusion showed no clear difference in adverse effects: toxic death (no definition provided) compared with bolus platinum infusion (low certainty).
1 finding from 1 review
Quality of life ‐ not reported · children with cancer treated with platinum‐based therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Ototoxicity according to NCI CTC v2 criteria with intra‐arterial platinum (combined asymptomatic and symptomatic disease) Exact test method not reported · children with cancer treated with platinum‐based therapy
Amifostine showed no clear difference in ototoxicity according to NCICTCv2 criteria with intra‐arterial… compared with no otoprotective intervention (low certainty).
1 finding from 1 review
Ototoxicity according to Brock criteria with intravenous platinum (combined asymptomatic and symptomatic disease) · children with cancer treated with platinum‐based therapy
Sodium thiosulfate probably leads to lower ototoxicity according to Brock criteria with intravenous platinum… compared with no otoprotective intervention (moderate certainty).
1 finding from 1 review
Overall survival with intravenous platinum (i.e. mortality/number of participants deceased) · children with cancer treated with platinum‐based therapy
Sodium thiosulfate showed no clear difference in overall survival with intravenous platinum (i.e. mortality/number of… compared with no otoprotective intervention (low certainty).
1 finding from 1 review
Event‐free survival · children with cancer treated with platinum‐based therapy
Sodium thiosulfate showed no clear difference in event‐free survival with intravenous platinum (i.e. number of… compared with no otoprotective intervention (low certainty).
1 finding from 1 review
Tumour response with intravenous platinum (complete and partial remission) · children with cancer treated with platinum‐based therapy
Sodium thiosulfate showed no clear difference in tumour response with intravenous platinum (complete and partial… compared with no otoprotective intervention (low certainty).
1 finding from 1 review
Adverse effects other than ototoxicity (≥ grade 3 according to NCICTCAEv3 criteria) with intravenous platinum · children with cancer treated with platinum‐based therapy
1 finding from 1 review
Ototoxicity according to NCI CTC v2 criteria with intravenous platinum (combined asymptomatic and symptomatic disease) Objective and subjective audiometric evaluations were performed, no further information provided · children with cancer treated with platinum‐based therapy
Amifostine showed no clear difference in ototoxicity according to NCICTCv2 criteria with intravenous platinum… compared with no otoprotective intervention (low certainty).
1 finding from 1 review
Ototoxicity according to modified Brock criteria with intravenous platinum (combined asymptomatic and symptomatic disease) Audiograms were performed, but no further information provided · children with cancer treated with platinum‐based therapy
Amifostine showed no clear difference in ototoxicity according to modified Brock criteria with intravenous… compared with no otoprotective intervention (low certainty).
1 finding from 1 review
Tumour response with intra‐arterial platinum (good and partial remission) · children with cancer treated with platinum‐based therapy
Amifostine showed no clear difference in tumour response with intra‐arterial platinum (good and partial… compared with no otoprotective intervention (low certainty).
1 finding from 1 review
Renal toxicity / vomiting/ cardiotoxicity (all grade 3 or higher according to NCI CTCv2 criteria) with intra‐arterial platinum · children with cancer treated with platinum‐based therapy
1 finding from 1 review
Quality of life ‐ not reported · children with cancer treated with platinum‐based therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Survival · children with cancer treated with platinum‐based therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Tumour response · children with cancer treated with platinum‐based therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found